Table 1 : Cytotoxicity of individual anticancer drugs in different cell lines.


Cell lines IC50 (µM)

  Volasertib Paclitaxela Doxorubicinb Mitoxantronec Cisplatind

SW620 1.38 + 0.19 0.032 + 0.009 ND ND 10.2 + 1.3
SW620 Ad300 1.54 + 0.22 38.2 + 4.2 ND ND 11.6 + 1.1
MCF-7 0.008 + 0.003 ND 0.31 + 0.02 ND 9.85 + 0.76
MCF-7 VP 0.011 + 0.007 ND 7.73 + 0.82 ND 9.16 + 0.84
S1 2.42 + 0.23 ND ND 0.083 + 0.012 2.45 + 0.41
S1M1 80 2.15 + 0.36 ND ND 115.2 + 12.5 3.16 + 0.29
HEK293 - - - - - -
pcDNA 6.52 + 0.41 0.041 + 0.012 0.022 + 0.008 0.61 + 0.25 2.10 + 0.28
ABCB1 5.93 + 0.26 0.926 + 0.121 ND ND 2.31 + 0.35
ABCC1 6.26 + 0.39 ND 0.32 + 0.05 ND 2.49 + 0.31
ABCG2 6.25 + 0.34 ND ND 34.2 + 4.1 2.56 + 0.29

aPaclitaxel is a probe substrate anticancer drug for ABCB1 (Pgp)
bDoxorubicin is a probe substrate anticancer drug for ABCC1 (MRP1)
cMitoxantrone is a probe substrate anticancer drug for ABCG2
dCisplatin is known to be a non-substrate for ABCB1, ABCC1 and ABCG2
ND = not determined.

To et al.Journal of Cancer Therapeutics and Research  2013 2:13DOI : 10.7243/2049-7962-2-13